Direct-to-patient healthcare company Ro announced that it is working with Eli Lilly (LLY) to launch the recently FDA-approved Zepbound KwikPen nationwide on its platform. “The prefilled, multi-dose pen offers a convenient way for patients to take the most effective GLP-1 medication available,” Ro said in a statement. The Zepbound KwikPen is available to cash-pay patients. Monthly pricing starts at $299 for the 2.5 mg starter dose and $399 for the 5 mg dose.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump’s Medicare GLP-1 drug plan to cost insurers ‘billions,’ Bloomberg reports
- IBB, IHI, XBI: Boost Your Portfolio with Healthcare Exchange-Traded Funds (ETFs)
- Trump Trade: President says Iran war will still take weeks
- Trump administration readying new pharmaceutical tariffs, FT reports
- Wegovy vs. Foundayo: Novo Nordisk’s “Record-Breaking” Run Meets the Eli Lilly (LLY) Challenge